
Bioscience company Chr. Hansen and Swiss biotech firm Lonza have obtained permission to launch the production of bacteria for pharmaceutical use in their production facilities in Denmark and Switzerland.
Health authorities from Denmark and Switzerland have run inspections and found that the two production facilities are suitable for the production of so-called live bio therapeutics, that is, beneficial bacteria to be used in medication.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app